Decheng Capital’s Roivant Sciences ROIV Stock Holding History

Decheng Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,279,700	Closed	-$14.4M	–	26
2023 Q4	$14.4M	Buy	+1,279,700	New	+$12.5M	4.02%	8

Other funds holding ROIV

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Decheng Capital's ROIV Position: Q1 2024 in Review

Decheng Capital sold out of Roivant Sciences (ROIV) in Q1 2024, closing a stake of 1,279,700 shares — an estimated $14.4M sold.

Decheng Capital first reported a position in ROIV in Q4 2023 and held it in 1 quarter. The position peaked at $14.4M in Q4 2023. 260 funds tracked by Wall St. Rank hold ROIV as of Q1 2024.

Decheng Capital reported no remaining Roivant Sciences position as of Q1 2024 after selling out during the quarter.
Decheng Capital sold 1,279,700 Roivant Sciences shares in Q1 2024, an estimated $14.4M.
Decheng Capital first reported a position in Roivant Sciences in Q4 2023 and held it in 1 quarter.
Decheng Capital's Roivant Sciences position peaked at $14.4M in Q4 2023.
260 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2024.

Based on Decheng Capital's 13F filing for Q1 2024, filed 14 May 2024.